Fluid therapy with L-lactate and/or pyruvate anions

Inactive Publication Date: 2004-09-28
BTG INT LTD
View PDF14 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

More particularly, this invention is directed to improved methods and optionally stable fluids for conventional administration to humans such as, (a) oral ingestion of an aqueous solution containing at least one of such anions, or a mixture of such anions, (b) parenteral therapy involving, for example, the intravenous administration of an aqueous solution containing at least one of such anions, or a mixture thereof, (c) dialysis therapy (hemo or peritoneal) using aqueous solutions containing at least one of such anions, (d) dialysis therapy (hemo or peritoneal) where acetic acid is replaced with at least one acid of the group consisting of l-lactate, pyruvate, .[.d-beta.

Problems solved by technology

Thus, the d-form has now been discovered to cause adverse and toxic effects when administered to mammals.
With continued administratio

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fluid therapy with L-lactate and/or pyruvate anions

Examples

Experimental program
Comparison scheme
Effect test

embodiments

The following examples are merely illustrative of the present invention and are not intended as a limitation upon the scope thereof.

examples 1-4

The following Table III illustrates particular solutions of this invention:

TABLE III (Values are in mMoles / Liter) Ex. No. Component Class I Class II Class III 1 l-lactate.sup.(1) 1000 Na.sup.+ 1000 2 pyruvate.sup.(2) 1000 Na.sup.+ 1000 3 l-lactate.sup.(3) 900 pyruvate 100 Na.sup.+ 1000 4 l-lactic acid 5 Table III footnotes: .sup.(1) For treatment of acidosis see Merck Handbook p 1866 12th edition. .sup.(2) For treatment of acidosis when severe reduction of [NAD.sup.+ ] / [NADH] is present (see USSN 748,232). .sup.(3) For treatment of acidosis when redox balance is desired (see USSN 748,232). .sup.(4) For use as an additive to a bicarbonate containing solution (see USSN 748,232).

examples 5-12

Illustrative examples of various physiological abnormalities which are treatable by using various starting solutions of the present invention are shown in Table IV below:

TABLE IV Exemplary Usenges Condition Where Useful Fluid Composition Route of and solution Cation(s) Anion(s) Administration, common name in mMoles / liter and Dose 5. Dehydration Na.sup.+ 130 Cl.sup.- 109 parenteral, (L-lactated K.sup.+ 3 l-lactate.sup.- 28 500 ml to 3 Ringers).sup.(1) Ca.sup.2+ 1.5 liters per day depending on severity and cause 6. Peritoneal Na.sup.+ 141 Cl.sup.- 101 Introperitoneal, Dialysis Ca.sup.2+ 1.75 l-lactate.sup.- 45 4 to 8, 2 liter (Dianeal.sup.(2) Mg.sup.2+ 0.75 bags per day w / 1.5% (also dextrose 83) Dextrose, Travenol).sup.(3) 7. Metabolic Na.sup.+ 156.1 l-lactate 156.1 parenteral or Acidosis oral, 10 ml to (Isotonic 1 L depending sodium l- on size lactate of patient solution).sup.(4) 8. Cardiac Mg.sup.+ 145 Cl.sup.- 115 Intracoronary Reperfusion Ca.sup.2+ 0.5 HCO.sub.3.sup.- 25 infusion ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to view more

Abstract

Electrolyte solutions are provided which are useful in electrolyte and fluid therapy, parenteral nutrition and dialysis. The Na:Cl ratio is normalized, plasma and cellular pH are normalized and cellular cofactor ratios are normalized in a manner which decreases toxicity over prior art solutions.

Description

BACKGROUND OF THE INVENTION1. Field of the InventionThis invention lies in the field of fluid therapy in humans, and more particularly in the field of aqueous solutions for parenteral, oral, dialysis, and irrigation therapy which employ at least one of l-lactate anions, pyruvate anions, d-betahydroxybutyrate anions, acetoacetate anions, or mixtures thereof in combination with selected cations.2. Prior ArtPreviously, I have provided improved electrolyte solutions for in vivo and in vitro usage which contain l-lactate and pyruvate anions, and / or d-betahydroxybutyrate and acetoacetate anions in respective defined ratios in combination with defined Na:Cl ratios; see my copending U.S. patent applications Ser. Nos. 748,232 and 747,792, both filed Jun. 24, 1985, and also my copending U.S. patent application Ser. Nos. 747,858 and 748,184, also filed on such date. However, it is now appreciated that the benefits of using l-lactate, pyruvate, d-betahydroxybutyrate, and / or acetoacetate anions ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K33/10A61K33/06A61K33/14A61K31/19A61M1/16A61M1/28A61K31/185C12N5/00
CPCA61K31/19A61K33/06A61K33/10A61K33/14A61M1/1654A61M1/287C12N5/0018C12N2500/12A61K2300/00
Inventor VEECH, RICHARD L.
Owner BTG INT LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap